Aarti Pharmalabs Balance Sheet Health
Financial Health criteria checks 5/6
Aarti Pharmalabs has a total shareholder equity of ₹17.6B and total debt of ₹2.9B, which brings its debt-to-equity ratio to 16.2%. Its total assets and total liabilities are ₹25.8B and ₹8.3B respectively. Aarti Pharmalabs's EBIT is ₹3.2B making its interest coverage ratio 21.7. It has cash and short-term investments of ₹943.2M.
Key information
16.2%
Debt to equity ratio
₹2.85b
Debt
| Interest coverage ratio | 21.7x |
| Cash | ₹943.17m |
| Equity | ₹17.57b |
| Total liabilities | ₹8.25b |
| Total assets | ₹25.82b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: AARTIPHARM's short term assets (₹13.5B) exceed its short term liabilities (₹6.9B).
Long Term Liabilities: AARTIPHARM's short term assets (₹13.5B) exceed its long term liabilities (₹1.3B).
Debt to Equity History and Analysis
Debt Level: AARTIPHARM's net debt to equity ratio (10.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if AARTIPHARM's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: AARTIPHARM's debt is well covered by operating cash flow (75.8%).
Interest Coverage: AARTIPHARM's interest payments on its debt are well covered by EBIT (21.7x coverage).